NanoViricides Inc. (NNVC)

[Doctor_Hari_Seldon]

Why consider investing in NNVC?

First and foremost, everyone must do their own due diligence! This is very important and universal!

Some investors simply like to follow smart money. While this approach is not always successful, it can have positive outcomes. Vanguard, one of the most well known for good solid investing, is considered by some to be part of the assemblage of ‘smart money’. Vanguard has bought and is holding NNVC. So has the ‘smart money’ house of Europe, Deutsche Bank, as well as many others.

What does NNVC offer? What makes it compelling to own?

The Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, when asked why he invested a total of $7 Million in the Company during the 2013 calendar year explained it this way; “As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing”.

NNVC therapeutic efficacy tests indeed have shown remarkable results. Standardized test protocols with mice specially developed by those in the medical research community to have human susceptibility traits were injected with 1000x viral loads required to ensure death. These standard protocols then measure efficacy by recording the time it takes to die for a treated animal versus the control animal. Even a few hours of delayed death can be quite meaningful. For NNVC, and unprecedentedly, large percentages actually survived! That is extraordinary efficacy!

The NNVC therapeutics also show similar comparable efficacy for both the injectable and oral forms.

To date, the NNVC therapeutics used in both forms show no apparent toxicity issues. Specific detailed testing being currently planned and prepared for to verify. This is one of the final activities prior to starting planned tests in humans under FDA protocols. A new facility is in final stages of construction to allow production of the quantities of the drug candidates needed for those human trials.

Don’t understand the technology? Could it be too good to be true? For further study, information about NNVC’s novel, proprietary anti-virus platform technology was published in a book by one of the world leading scientific reference publication houses; the CRC Press Publications. The book entitled Bionanotechnology II: Global Prospects, provides an in-depth presentation of the NanoViricides platform technology, evidence for how nanoviricides are believed to act plus dramatic results of nanoviricides specifically targeting certain viral diseases, such as HIV and the ocular disease, epidemic keratoconjunctivitis (EKC). Please reference the link below for further information in that regard;

http://books.google.com/books?id=K_Wy4Fq-QcMC&pg=PA141&lpg=PA141&dq=Bionanotechnology+II:+Global+Prospects+Nanoviricides+-+A+Novel+Approach+to+Antiviral+Therapeutics&source=bl&ots=XWUh8uwFPy&sig=CxX9RQd5RgDhksPyNYl_1dw0lh0&hl=en&sa=X&ei=-50SU5XlEMWkyAHil4DIDQ&ved=0CCcQ6AEwAg#v=onepage&q=Bionanotechnology%20II%3A%20Global%20Prospects%20Nanoviricides%20-%20A%20Novel%20Approach%20to%20Antiviral%20Therapeutics&f=false

NNVC’s work is far enough along and superior enough that it was awarded an orphan drug development designation in both the United States and in Europe! Even the Aussies have interest!

The FDA orphan designation also means NNVC is now eligible for a FDA Priority Review Voucher (PRV). PRVs are transferable and can be worth upwards of one-half Billon Dollars or more in the pharmaceutical development market place! What a sudden shot in the arm that would be! It is almost like a hugely positive Wild Card hanging out there!

Dr. Eva Harris, Professor of infectious diseases at UC Berkeley, president of the Sustainable Sciences Institute., a well renowned medical researcher whose papers and studies into the pathogenesis and epidemiology of infectious diseases have been of benefit to the medical community for years has performed independent efficacy studies of NNVC’s anti-viral candidate for Dengue Fever. Dr. Harris’s testing indicated a very high level in the efficacy of the Nanoviricide against the Denque fever virus in lethal animal models specially designed to yield highly controlled and applicable studies and data. Her work provides a strong independent confirmation that NNVC science has validity and high potential.

General investing principles often use insider buys as an indication of insider confidence. A major NNVC insider has indeed purchased more shares from the open market in recent weeks. Typically this is considered a very positive sign.

A uniquely valuable aspect of NNVC therapeutics are that they appear to be of a programmable or modifiable design that can potentially target nearly any type of virus in a very short time, potentially in a matter of weeks. This is very important considering that it is not if, but when, the next major pandemic hits the world.

As compared to oseltamivir, results demonstrated that oral administration of two different NNVC FluCide drug candidates produced significantly greater reduction in viral loads!
NNVC’s lead anti-HIV candidate also achieved a long term anti-HIV effect with a much shorter dosing regimen and a markedly lower total drug dose than that of the HAART Drug Cocktail therapy. Treatment with the lead anti-HIV nanoviricide reduced HIV levels and protected the human T cells (CD4+,CD8+) to the same extent as treatment with the HAART cocktail in the SCID/hu Thy/Liv mouse model.

In addition to other patents surrounding NNVC’s proprietary technologies, NNVC has also received US Patent (No. 8,173,764) for "Solubilization and Targeted Delivery of Drugs with Self-Assembling Amphiphilic Polymers." The patent term is expected to last through October 1, 2026, including an anticipated extension, with the possibility of further extensions in compensation for time spent in clinical trials.

NNVC is also working with the very reputable Viroclinics Biosciences in the Netherlands to test various Nanoviricdes as therapeutics for a range of emerging world viral threats.

Are there any negatives? There typically is always something of at least some concern. Currently the following come to mind;
While NNVC’s product efficacy tests and evaluations have shown excellent results, their move toward human clinical trials will undoubtedly incur a greater expenditure. While the company has indicated it has sufficient funding to make it to the human trials, any delays might produce a need for additional funds.
Additionally, there is a current legal matter which appears to be not settled in its entirety. While from a developmental company funding standpoint and from an industry comparative and historical perspective, NNVC stock dilution has been minimal suggesting good stewardship of funding by providing high achievement results per unit dollar invested, there is some questions brought about by the legal actions as to possible conflicts of interests. Of note is that the plaintiff indicates a desire to not a significant hostile threat to the company and has made clear that the intent of actions is primarily to improve corporate governance, and that as an investor in the company, believes in its prospects and desire NNVC it to ultimately succeed. How any such resulting court actions might unfold is uncertain at this time. This type of issue is not uncommon with scientific based start-ups where the principals desire strong control over their inventions and might not be as astute to all issues surrounding corporate governance, especially as the company’s activities expand with growth and success in the product development.

No company perfectly executes its growth path. So far though, NNVC does appear to have managed their funds effectively to produce a potential game changing anti-viral therapeutic product in a relatively short period of time with a reasonable expenditure. For that they should be commended.

Above all, remember, do your own DD. Don’t blindly follow. Know your risk level. Beware of misinformation, whether it be intentional or not.

Read, study, think; it is a process that behooves us all.

Wishing all the best of good buys!
HS